Information  X 
Enter a valid email address

Futura Medical PLC (FUM)

  Print      Mail a friend       Annual reports

Tuesday 25 June, 2019

Futura Medical PLC

Director/PDMR Shareholding

RNS Number : 3971D
Futura Medical PLC
25 June 2019
 

Director/PDMR Dealings

 1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

James Barder

2

Reason for the notification

a)

Position/status

Chief Executive Officer

b)

Initial notification/Amendment

Amendment - additional disclosure to the Director Dealing announcement dated 19 November 2018 clarifying a voluntary surrender of options.  All other details were and remain correct.

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Futura Medical plc

b)

LEI

21380053QLT46UNV2303

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary Shares of 0.2 pence each

 

 

GB0033278473

b)

Nature of the transaction

Surrender of options over ordinary shares

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

61.50

250,000

 

d)

Aggregated information

-         Aggregated volume

-         Price

N/A

e)

Date of the transaction

16th November 2018

f)

Place of the transaction

Outside a trading venue

 

 

For further information please contact:

Futura Medical plc 
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO
Email: [email protected]
Tel: +44 (0) 1483 685 670

 

Liberum (Nominated Adviser and Broker)
Bidhi Bhoma
Euan Brown
Kane Collings
Tel: +44 (0) 20 3100 2000

 

For media enquiries please contact:
Optimum Strategic Communications
Mary Clark/ Hollie Vile/ Ellie Blackwell
Email: [email protected]
Tel: +44 (0) 203 950 9144

 

Notes to editors:

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.

 

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com

 

 

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHLLFVERRIEFIA

a d v e r t i s e m e n t